Wnt9b-dependent FGF signaling is crucial for outgrowth of the nasal and maxillary processes during upper jaw and lip development

Yong-Ri Jin¹, Xiang Hua Han¹, Makoto M. Taketo² and Jeong Kyo Yoon¹,*

SUMMARY
Outgrowth and fusion of the lateral and medial nasal processes and of the maxillary process of the first branchial arch are integral to lip and primary palate development. Wnt9b mutations are associated with cleft lip and cleft palate in mice; however, the cause of these defects remains unknown. Here, we report that Wnt9b⁻/⁻ mice show significantly retarded outgrowth of the nasal and maxillary processes due to reduced proliferation of mesenchymal cells, which subsequently results in a failure of physical contact between the facial processes that leads to cleft lip and cleft palate. These cellular defects in Wnt9b⁻/⁻ mice are mainly caused by reduced FGF family gene expression and FGF signaling activity resulting from compromised canonical WNT/β-catenin signaling. Our study has identified a previously unknown regulatory link between WNT9B and FGF signaling during lip and upper jaw development.

KEY WORDS: WNT, β-Catenin, FGF signaling, Orofacial morphogenesis, Cleft lip, Cleft palate, Mouse

INTRODUCTION
Upper lip and nose development in mice starts around embryonic day (E) 9.5, when neural crest cells from the dorsal region of the fore- and mid-brain migrate ventrally and form mesenchyme within an unpaired frontonasal prominence rostral to the telencephalon (Serbedzija et al., 1992; Osumi-Yamashita et al., 1994; Kontges and Lumsden, 1996; Creuzet et al., 2005; Minoux and Rijli, 2010). In parallel, maxillary processes (MxPs) derived from the first branchial arch (BA1) become evident lateral to the stomodeum and rostral to the mandibular processes (MxPs). At E10, within the ventrolateral region of the frontonasal prominence, the medial nasal (MNP) and lateral nasal (LNP) processes bulge and outgrow around the periphery of the nasal placode in a horseshoe shape, forming the nasal pit. In the E10.5 mouse embryo, mesenchymal cells within the MNP, LNP and MxP divide rapidly (Jiang et al., 2006). The lateral growth of the MxP pushes the nasal pits toward the middle face region. The ventral tip of the MNP extends further rostrally and ventrolaterally to begin fusion with both the LNP and the MxP at the medial end of their boundary junction. During fusion of these processes, apoptosis of epithelial cells occurs in the seam of the contacting MNP and LNP, resulting in the connection of mesenchymal cell compartments. By E11.5, the nostrils and lip are correctly formed by the completion of fusion of the MNP, LNP and MxP (Jiang et al., 2006; Song et al., 2009). In addition, the expanding MxP pushes the nostrils into the more medial region. Failure or delay of outgrowth and fusion of the NPs and MxP lead to cleft lip with or without cleft palate (CL/P) (Szabo-Rogers et al., 2010; Dixon et al., 2011).

The significance of the WNT signaling pathway in regulating facial morphogenesis is suggested by expression of various WNT ligand genes within the facial prominences (Summerhurst et al., 2008; Geetha-Loganathan et al., 2009). Canonical WNT signaling reporter transgenes such as TopGAL, BATgal and Axin2-lacZ are highly expressed in the facial prominences and their derivatives, further indicating a potential role of WNT/β-catenin signaling during facial development (Maretto et al., 2003; Brugmann et al., 2007; Al Alam et al., 2011).

Previous studies of genetically altered mice in which the key components of WNT signaling are disrupted further suggest the crucial roles of WNT signaling in facial development. For instance, ablation of the canonical WNT signaling receptor gene Lrp6 causes hypoplasia of the facial processes accompanied by reduced cell proliferation within the NPs and CL/P in mice (Song et al., 2009). These mutant mice display severely reduced WNT/β-catenin signaling activity and decreased expression of the WNT target genes Msx1 and Msx2 within the facial processes.

Both inactivation and constitutive activation of Ctnnb1, which encodes β-catenin, a central mediator of canonical WNT signaling, in the embryonic facial domains result in severe facial defects (Braut et al., 2001; Reid et al., 2011; Wang et al., 2011). Facial ectoderm-specific deletion or activation of Ctnnb1 result in downregulation or upregulation, respectively, of ectodermal FGF family gene expression, showing that canonical WNT signaling controls ectoderm FGF signaling during facial development (Reid et al., 2011; Wang et al., 2011). Mice lacking the R-spondin 2 (Rsop2) gene, which encodes a novel WNT agonist, exhibit hypoplasia and disrupted patterning of the Mxp and cleft of the secondary palate with very low penetration of cleft lip (Yamada et al., 2009; Jin et al., 2011).

Among the WNT genes expressed in the facial prominences, the developmental function of the individual genes and their association with craniofacial abnormalities including CL/P are not fully understood (Menezes et al., 2010). Wnt3 and Wnt9b are suggested to play roles in CL/P. Homozygous Wnt3 mutation in humans is associated with CL/P (Niemann et al., 2004). The
association of Wnt9b with CL/P arises from the study of A/WySn mice. Approximately 5-30% of A/WySn mice display CL/P and the two genetic loci, clf1 and clf2, have been identified by linkage to CL/P. The clf1 locus is located in the proximity of Wnt9b (Juriloff et al., 2005). By genetic complementation, A/WySn mice were confirmed to be homozygous for a hypomorphic Wnt9b allele (Juriloff et al., 2006). Consistent with the A/WySn study, Wnt9b null mice also show a higher frequency of CL/P than A/WySn mice (Juriloff et al., 2006). However, the nature of the embryological defects in Wnt9b null mice that lead to CL/P and the mechanism by which Wnt9b regulates the morphogenesis of facial structures during embryogenesis remain unknown.

In the present study, we investigated facial morphogenesis in Wnt9b null embryos. We found that loss of the Wnt9b gene caused retarded outgrowth and failed contact of the NPs and MxP, resulting in CL/P at a later stage. These defects were a direct consequence of reduced cell proliferation without any notable increase of cell apoptosis within mesenchymal cells of the NPs and MxP. Furthermore, these defects were associated with downregulation of FGF signaling, which acts as a mitogenic signal for mesenchymal cells in the NPs and MxP, as a result of compromised WNT/β-catenin signaling in Wnt9b−/− embryos. Our findings have identified a previously unknown role of Wnt9b in regulating the proliferation of NP and MxP mesenchymal cells by positively modulating ectoderm-derived FGF signaling.

**MATERIALS AND METHODS**

**Animals**

Mice carrying the Wnt9b conditional null (Wnt9blop/lop) allele (Carroll et al., 2005) in a genetic background outcrossed with Swiss Webster were kindly provided by Thomas J. Carroll (University of Texas Southwestern Medical Center). We crossed these mice with C57BL/6 mice once and the offspring were maintained in the mixed genetic background. A null allele (Juriloff et al., 2006). Consistent with the two genetic loci, clf1 and clf2, have been identified by linkage to CL/P. The clf1 locus is located in the proximity of Wnt9b (Juriloff et al., 2005). By genetic complementation, A/WySn mice were confirmed to be homozygous for a hypomorphic Wnt9b allele (Juriloff et al., 2006). Consistent with the A/WySn study, Wnt9b null mice also show a higher frequency of CL/P than A/WySn mice (Juriloff et al., 2006). However, the nature of the embryological defects in Wnt9b null mice that lead to CL/P and the mechanism by which Wnt9b regulates the morphogenesis of facial structures during embryogenesis remain unknown.

In the present study, we investigated facial morphogenesis in Wnt9b null embryos. We found that loss of the Wnt9b gene caused retarded outgrowth and failed contact of the NPs and MxP, resulting in CL/P at a later stage. These defects were a direct consequence of reduced cell proliferation without any notable increase of cell apoptosis within mesenchymal cells of the NPs and MxP. Furthermore, these defects were associated with downregulation of FGF signaling, which acts as a mitogenic signal for mesenchymal cells in the NPs and MxP, as a result of compromised WNT/β-catenin signaling in Wnt9b−/− embryos. Our findings have identified a previously unknown role of Wnt9b in regulating the proliferation of NP and MxP mesenchymal cells by positively modulating ectoderm-derived FGF signaling.

**Embryos**

Embryos were fixed with 2% glutaraldehyde/2% paraformaldehyde in PBS buffer followed by OOsO4 and gradually dehydrated in ethyl alcohol. The embryos were critical point dried under CO2 and sputter coated with 30 nm gold particles. Images were obtained using an AMRay 1000 scanning electron microscope (Gold International Machinery) and xRF digital capture system at the Scanning Electron Microscopy Facility of the University of Maine at Orono.

**BrdU incorporation and apoptosis assays and immunofluorescence staining**

For BrdU incorporation assays, pregnant mice (E10.5 or E13.5) were intraperitoneally injected with BrdU (100 mg/kg body weight, Invitrogen) for 15 (E10.5-11 embryos) or 30 (E13.5 embryos) minutes prior to sacrifice. The incorporated BrdU was detected immunohistochemically in cryosections using a cell proliferation kit (Invitrogen). Apoptotic cells were detected in TdT-mediated dUTP nick-end labeling (TUNEL) assay using an in situ cell death detection kit (Roche Applied Science). Immunofluorescence staining with anti-phospho-histone H3 (1:100 dilution, Cell Signaling), anti-activated caspase 3 (1:100, Cell Signaling) and anti-PY489-β-catenin (1:100, Developmental Studies Hybridoma Bank) was performed on cryosections.

**qRT-PCR and western blot analysis**

Total RNA was isolated at least in triplicate from NP/MxP tissues freshly dissected from embryos and from cultured NP/MxP explants using Trizol (Sigma). Quantitative real-time (qRT) PCR using cDNA (10 ng total RNA equivalent) synthesized using the Proscript cDNA Synthesis Kit (New England Biolabs) was performed in duplicate per sample as described (Jin et al., 2011). Expression level was normalized to Gapdh and E-cadherin (Cdh1; when epithelial-specific genes were examined). PCR primers are listed in supplementary material Table S1 and as described previously (Jin et al., 2011).

Protein lysates (10 μg), prepared by homogenizing the tissues or cultured cells in RIPA lysis buffer [10 mM Tris-Cl pH 7.2, 2 mM EDTA, 150 mM NaCl, 0.5% Nonidet P40, 0.1% SDS, 50 mM NaF, 1% sodium deoxycholate, 1 mM PMSF, 1× protease inhibitor mixture set V (EMD Chemicals), 0.2 mM sodium vanadate] were used in western blot analysis. Primary antibodies (all 1:1000 dilution) were against phospho-LRP6 (Cell Signaling), LRP6 (Santa Cruz Biotechnology), phospho-c-JUN (Cell Signaling), phospho-JNK1/2 (Cell Signaling), JNK1/2 (Cell Signaling), phospho-ROCK2 (Abcam), ROCK2 (Santa Cruz Biotechnology), phospho-ERK1/2 (Cell Signaling), ERK1/2 (Cell Signaling) and α-tubulin (Santa Cruz Biotechnology). The horseradish peroxidase (HRP) signal conjugated with secondary antibodies was developed using the Super Signal West Dura Kit (Thermo Scientific/Pierce). The signals were quantified using ImageJ software, and each experiment was performed in triplicate.

**RHOA family small GTPase assays**

The small GTPase assay was performed using the RHOA and RAC1/CDC42 activation assay kit (Millipore) according to the manufacturer’s instructions. Briefly, NP/MxP tissues were dissected in cold PBS from E10.5 wild-type or mutant embryos (n=7) and homogenized in lysis buffer comprising 20 mM HEPES (pH 7.4), 50 mM NaF, 0.2 mM MgCl2, 20% glycerol, 0.1% Triton X-100, 1 mM PMSF, 0.2 mM sodium orthovanadate and 1× protease inhibitor cocktail set V (EMD Chemicals). Lysates (500 μg) prepared in duplicate (14 wild-type and 14 mutant embryos) were used for detection of the activated RHOA family small GTPase. Positive controls were produced by adding GTP into the lysates to activate the GTPases.

**Skeletal preparation, β-galactosidase staining and whole-mount in situ hybridization**

Skeletal preparation and measurement, whole-mount β-galactosidase staining using X-Gal substrate, and whole-mount in situ hybridization were performed as described (Jin et al., 2011). The stained embryos were processed for cryosections. Fetuses/embryos and the cryosections were photographed using a Zeiss Stemi SV6 stereomicroscope and Zeiss Axioskop microscope with a Zeiss AxioCam digital camera.

**Scanning electron microscopy**

Embryos were fixed with 2% glutaraldehyde/2% paraformaldehyde in PBS buffer followed by OOsO4 and gradually dehydrated in ethyl alcohol. The embryos were critical point dried under CO2 and sputter coated with 30 nm gold particles. Images were obtained using an AMRay 1000 scanning electron microscope (Gold International Machinery) and xRF digital capture system at the Scanning Electron Microscopy Facility of the University of Maine at Orono.
FGFs and WNT9B proteins (R&D) were added to the culture medium as indicated. NP603 (EMD Chemicals), a specific FGF receptor inhibitor, was resuspended in DMSO and added to culture medium at 5 μM.

**Cell proliferation and migration assays**
For the cell proliferation assay, 1×10^6 cells were seeded in each well of 6-well plates (Nunc) in triplicate. After 3 days in culture, total cell number was determined using a Vi-Cell automated cell viability analyzer (Beckman Coulter). For the wound-healing assay, 1×10^6 cells were seeded and cultured in 6-well plates overnight. The surface of the cell layer was scratched with a 1-ml pipette tip, followed by washing with PBS, and fresh medium containing FGF or WNT9B proteins was added. Phase-contrast images were taken after culturing cells for 16 hours. For the migration assay, 4×10^4 cells were seeded on top of the filter (8 μm pore size) of 96-well Transwell plates (Corning). DMEM containing control bovine serum albumin (400 ng/ml) or WNT9B (400 ng/ml) protein was added into the bottom chambers (n=6). After 8 hours of culture, migrated cells were counted after DAPI staining.

**Sample numbers and statistical analysis**
Three or four embryos or fetuses of each genotype were used in experiments unless indicated otherwise. The experimental data were analyzed using a non-paired Student’s t-test. Statistical significance was set at P<0.05.

**RESULTS**
**Wnt9b null mice display CL/P and skeletal abnormalities in the upper jaw**
To determine the function of Wnt9b during facial development, we examined the craniofacial morphology of Wnt9b^-/- mice at E18.5. Consistent with previous reports, Wnt9b^-/- mice developed CL/P (unilateral CL/P, n=2/15; bilateral CL/P, n=13/15) (Fig. 1A-D), confirming that Wnt9b is required for proper development of the lip and palate. The penetrance of the CL/P phenotype in Wnt9b^-/- mice was 100% in the mixed genetic background, which is higher than previously reported (Carroll et al., 2005; Juriloff et al., 2006), probably owing to different genetic backgrounds.

Histological analyses during palatogenesis showed that initial downward growth of the palatal shelves occurred normally in Wnt9b^-/- mice at E12.5-13.5 (supplementary material Fig. S1E,F). A failure or delay of horizontal elevation of the palatal shelves that subsequently led to failed midline contact was observed in Wnt9b^-/- mice at E14.5 (Fig. 1E,F). No apparent defects in cell proliferation (supplementary material Fig. S1A-C) or apoptosis (data not shown) within the palatal shelves or in their fusion ability (supplementary material Fig. S1G-J) were observed in Wnt9b^-/- mice, indicating that palatogenesis defects in Wnt9b^-/- mice are not intrinsic to the palatal shelves. These results are consistent with the absence of Wnt9b expression in the palate shelves (Lan et al., 2006; He et al., 2011).

We analyzed craniofacial bone and cartilage structures in Wnt9b^-/- mice at E18.5. There was no obvious difference in the dimension of the skull, including length and width, in Wnt9b^-/- mice (Fig. 1G,H; supplementary material Fig. S2). However, several skeletal components of the upper jaw were either missing or malformed (Fig. 1I-L). For instance, the premaxilla (pmx) of Wnt9b^-/- mice was much smaller than that of wild-type mice and failed to connect. The palatine processes of both premaxilla and maxilla (pppx and ppmx) were underdeveloped and remained unfused (n=12/12). Interestingly, although some Wnt9b^-/- mice displayed unilateral cleft lip, their primary palate skeleton, including pppx and ppmx, was defective bilaterally. Taken together, loss of Wnt9b caused CL/P with developmental defects of the upper jaw skeleton.

**Fig. 1. Cleft lip with cleft palate (CL/P) and craniofacial skeletal defects in Wnt9b^-/- mice.** (A,B) Front facial views of wild-type and Wnt9b^-/- fetuses at E18.5. Arrows indicate the bilateral cleft lip. (C,D) Ventral view of the lip and palate in E18.5 fetuses. The lower jaw was removed for a better view of the palate. Cleft of the secondary palate is indicated by arrows. (E,F) Coronal sections of the facial region of E14.5 embryos. Arrow indicates cleft of the secondary palate. (G-L) Lateral (G,H) and ventral (I-L) views of wild-type and Wnt9b^-/- skulls at E18.5. The mandible was removed for a better view of the skull in L. The pmx bone is well developed in wild-type mice, whereas Wnt9b^-/- pmx bone is underdeveloped and separated into two pieces due to cleft lip (arrowheads). mc, Meckel’s cartilage; mx, maxillar; ns, nasal septum; pmx, premaxilla; ppmx, palatal process of maxilla; pppx, palatal process of premaxilla; ps, palatal shelf; t, tongue.

**Loss of Wnt9b causes reduced outgrowth and contact failure of the NP and MxP**
The upper lip in mice is formed by a coordinated outgrowth and fusion of the MxP of BA1 with the LNP and MNP by E11.5. To investigate whether developmental defects of these processes are
associated with CL/P in Wnt9b−/− mice, embryos were examined by scanning electron microscopy. No morphological defects were apparent in Wnt9b−/− embryos prior to E10.5. Reduced invagination of the nasal pit, especially near the posterior region, was seen at E10.5 (arrow in Fig. 2A,B; n=2). At E11, hypoplasia of the LNP and MNP became evident and the MNP failed to extend toward the LNP in Wnt9b−/− embryos, in contrast to wild-type embryos (Fig. 2C-F; n=2). Approximately half a day later in gestation, Wnt9b−/− embryos showed a clear bilateral gap between the MNP and the medial end of the fused LNP and MxP (Fig. 2G,H; n=2).

Reduced cell proliferation within the mesenchyme of the NP and MxP of Wnt9b−/− embryos

To investigate whether hypoplasia and failed fusion of the three processes are associated with specific cellular defects within the processes, we examined cell proliferation and apoptosis in Wnt9b−/− embryos. BrdU incorporation after pulse labeling and presence of phospho-histone H3, a marker for mitotic cells in G2/M phase, were used to assess cell proliferation. A significant reduction in the numbers of BrdU-positive and phospho-histone H3-positive cells was detected mainly in the mesenchymal compartment of both the NP and MxP of Wnt9b−/− embryos at E10.5 (Fig. 3).

In wild-type embryos, cell apoptosis examined by activated caspase 3 (aCasp3) immunostaining and TUNEL assay appeared to be a rare event within the processes (supplementary material Fig. S3A). Apoptosis was detected in the epithelial seam in the fusion zone of the MNP, LNP and MxP of wild-type embryos at E10.5 (arrow in supplementary material Fig. S3A). By contrast, no apoptosis was observed in the posterior tips (prospective fusion zone) of the MNP and LNP in Wnt9b−/− embryos at E10.5 (supplementary material Fig. S3B). However, despite the failed contact and fusion, some apoptosis was observed in the end region of the MNP and LNP of Wnt9b−/− embryos at E11, suggesting delayed development of the NPs and MxP (data not shown). Comparable results were obtained by TUNEL labeling (data not shown).

We further determined whether fusion between the NP and MxP is defective in Wnt9b−/− embryos. The NP and MxP dissected from Wnt9b−/− embryos at E11-11.5 efficiently fused (n=7/7) in ex vivo facial explant culture (supplementary material Fig. S3C-E).

Taken together, these results indicate that CL/P in Wnt9b−/− mice is likely to be caused by retarded and/or delayed outgrowth and subsequent failure of physical contact of the NP and MxP, primarily owing to the cell proliferation defect of mesenchymal cells.

WNT9B specifically regulates canonical WNT/β-catenin signaling within the NP and MxP

WNT9B activates both WNT/β-catenin and WNT/planar cell polarity (PCP) signaling during kidney development (Carroll et al., 2005; Karner et al., 2011) and in HEK293T cells (data not shown). To determine whether ablation of Wnt9b attenuates WNT/β-catenin signaling within craniofacial structures, we examined expression of a WNT/β-catenin signaling reporter, TopGAL, in Wnt9b−/− embryos. At E10.5, TopGAL expression was significantly reduced in both surface ectodermal and underlying mesenchymal cells of the NPs and MxP in Wnt9b−/− mutants compared with wild-type embryos (black arrows in Fig. 4A-D), suggesting that Wnt9b expressed in ectoderm regulates WNT/β-catenin signaling in both ectodermal and mesenchymal cells of the NPs and MxP. Surprisingly, there was no reduction of TopGAL expression in the MdP of Wnt9b−/− embryos (white arrows in Fig. 4A,B), despite robust Wnt9b expression in the MdP ectoderm. This might explain why no mandible defect was observed in Wnt9b−/− mutants and also suggests that Wnt9b function in mandibular arch development is not essential, possibly being compensated by other WNT genes expressed in the MdP.

In addition, presence of the activated β-catenin protein, the phosphorylated LRP6 receptor and expression of Axin2 were severely reduced in these facial processes of Wnt9b−/− embryos (Fig. 4E-G and Fig. 7I). Expression of the WNT/β-catenin signaling target genes Msx1 and Msx2 (Song et al., 2009), which are expressed in mesenchymal cells within the NPs and MxP (Gauchat et al., 2000; Alappat et al., 2003; Ishii et al., 2005), was also reduced in Wnt9b−/− embryos (Fig. 4H-K and Fig. 7I).

To confirm that Wnt9b function is associated with WNT/β-catenin signaling, we treated the NP/MxP explants isolated from TopGAL transgenic embryos with recombinant WNT9B protein. The WNT9B protein effectively increased TopGAL transgene expression in both whole (ectoderm/mesenchyme) and mesenchymal explants (Fig. 5A-D). In similar explant cultures, WNT9B robustly activated expression of the WNT/β-catenin signaling targets Axin2, Msx1 and Msx2 and inhibited Raldh3 (Aldh1a3 – Mouse Genome Informatics), which is negatively
regulated by WNT/β-catenin signaling activity (Song et al., 2009) (Fig. 5E,F; supplementary material Fig. S4A). WNT9B also efficiently rescued the reduced Axin2, Msx1 and Msx2 expression in Wnt9b−/− explants (supplementary material Fig. S4A).

We next tested whether the defects associated with loss of Wnt9b are rescued in vivo by activation of β-catenin signaling. When LiCl, a GSK3β inhibitor that activates WNT/β-catenin signaling, was administered in utero, the elevated Raldh3 expression in Wnt9b−/− embryos (Fig. 5G,H) was effectively reversed (Fig. 5I,J). This rescue effect was further confirmed in NP/MxP tissues isolated from embryos after in utero LiCl administration by qRT-PCR, as reduced expression of Axin2, Msx1 and Msx2 and increased expression of Raldh3 in Wnt9b−/− embryos were reversed by LiCl (Fig. 5K). Taken together, these results confirmed that WNT/β-catenin signaling was severely compromised in the NPs and MxP of Wnt9b−/− embryos.

Fig. 4. Disruption of WNT/β-catenin signaling in Wnt9b−/− embryos. (A-D) TopGAL expression detected by colorimetric staining of β-galactosidase activity in wild-type and Wnt9b−/− mouse embryos. Black arrows indicate the NPs where significantly reduced TopGAL expression was observed in Wnt9b−/− embryos. There was no reduction of TopGAL expression in the MdP (white arrow in B). Dotted white lines in A and B indicate the plane of sections shown in C and D, respectively. Decreased TopGAL expression was apparent in both surface ectoderm and mesenchyme of the NPs (C,D). (E,F) Immunofluorescent staining of active β-catenin protein (green) in the facial processes at E11.0. (G) Western blot analysis of phosphorylated LRP6 in NP and MxP tissue lysates. Total LRP6 level provided a protein loading control. Signal levels from the triplicate samples were quantified using ImageJ and are presented as mean±s.e.m. *P<0.05, Student’s t-test. (H-K) Msx1 and Msx2 expression in E10.5-11 embryos was determined by whole-mount in situ hybridization. Arrowheads indicate the reduced expression domains in Wnt9b−/− embryos. mdp, mandibular process of branchial arch 1; Inp, lateral nasal process; mnp, medial nasal process; mxp, maxillary process.
Deletion of Wnt9b has no obvious effect on WNT/PCP signaling
To determine whether loss of Wnt9b influences non-canonical WNT/PCP signaling activity, we examined activation of RHOF, RAC1 and CDC42, three small GTPases key to the WNT/PCP pathway, in tissue lysates prepared from the NP and MxP of E10.5 embryos. No differences in the activation of these proteins were observed between Wnt9b−/− and wild-type embryos (Fig. 6A). We also found no significant differences in the levels of phosphorylated JNK1/2 (MAPK8/9 – Mouse Genome Informatics) and ROCK2, two kinases activated by RHOF/RAC1/CDC42, between Wnt9b−/− and wild-type embryos (Fig. 6B). Finally, immunostaining of phosphorylated c-JUN, a target for activated JNK, did not show any differences between wild-type and Wnt9b−/− embryos, except in the fusion zone of the MNP and LNP (Fig. 6C,D). This phosphorylation of c-JUN is likely to be associated with cell apoptosis in wild-type embryos (supplementary material Fig. S3A,B) (Jiang et al., 2006) but not with non-canonical WNT/PCP signaling. Therefore, we conclude that unlike kidney development, there was no significant downregulation of several FGF family genes within the facial processes in Wnt9b−/− embryos at E10.5-11 (Fig. 7), whereas Bmp4 and Shh expression was not modified (supplementary material Fig. S5). Expression of Fgf8, Fgf10 and Fgf17 was either absent or severely reduced in the LNP and MNP at E10.5 (Fig. 7A-I). Additionally, Fgf8 and Fgf10 expression remained reduced in the NPs of Wnt9b−/− embryos at E11 (Fig. 7C,D; data not shown).

To determine whether these FGF genes are regulated by WNT/β-catenin signaling activated by WNT9B, we examined their expression in the NP/MxP explants treated with WNT9B protein. WNT9B significantly induced the expression of three FGF genes in wild-type explants and effectively reversed the reduced FGF gene expression in Wnt9b−/− explants (supplementary material Fig. S4A). Consistent with these results, reduced FGF gene expression in Wnt9b−/− embryos was efficiently reversed by in utero treatment with LiCl (supplementary material Fig. S4B). We next examined FGF gene expression in E10.5 embryos in which β-catenin is constitutively activated within the ectoderm of the NP and MxP by Foxg1-Cre-mediated recombination of the Cmnb1+/loxP/Eco3 allele (Harada et al., 1999). All three FGF genes, as well as Axin2, were highly induced by activated β-catenin, whereas Raldh3 expression decreased (Fig. 7J).

Ectodermal FGFs induced by Wnt9b regulate proliferation of facial process mesenchymal cells
To determine whether reduced ectodermal expression resulted in a decrease in FGF signaling in the facial processes, we evaluated phosphorylation of ERK1/2 (MAPK3/1 – Mouse

There was no significant downregulation of several FGF family genes within the facial processes in Wnt9b−/− embryos at E10.5-11 (Fig. 7), whereas Bmp4 and Shh expression was not modified (supplementary material Fig. S5). Expression of Fgf8, Fgf10 and Fgf17 was either absent or severely reduced in the LNP and MNP at E10.5 (Fig. 7A-I). Additionally, Fgf8 and Fgf10 expression remained reduced in the NPs of Wnt9b−/− embryos at E11 (Fig. 7C,D; data not shown).

To determine whether these FGF genes are regulated by WNT/β-catenin signaling activated by WNT9B, we examined their expression in the NP/MxP explants treated with WNT9B protein. WNT9B significantly induced the expression of three FGF genes in wild-type explants and effectively reversed the reduced FGF gene expression in Wnt9b−/− explants (supplementary material Fig. S4A). Consistent with these results, reduced FGF gene expression in Wnt9b−/− embryos was efficiently reversed by in utero treatment with LiCl (supplementary material Fig. S4B). We next examined FGF gene expression in E10.5 embryos in which β-catenin is constitutively activated within the ectoderm of the NP and MxP by Foxg1-Cre-mediated recombination of the Cmnb1+/loxP/Eco3 allele (Harada et al., 1999). All three FGF genes, as well as Axin2, were highly induced by activated β-catenin, whereas Raldh3 expression decreased (Fig. 7J).

Ectodermal FGFs induced by Wnt9b regulate proliferation of facial process mesenchymal cells
To determine whether reduced ectodermal FGF gene expression resulted in a decrease in FGF signaling in the facial processes, we examined phosphorylation of ERK1/2 (MAPK3/1 – Mouse
We next investigated whether WNT9B and FGFs are mitogenic for facial process mesenchymal cells. WNT9B treatment did not enhance the proliferation of mesenchymal cells isolated from the NP and MxP of E10.5 embryos (Fig. 8E). By contrast, both FGF8 and FGF10 efficiently enhanced proliferation of these cells (Fig. 8F). Furthermore, proliferation of mesenchymal cells prepared from \( Wnt9b^{−/−} \) embryos was also enhanced by FGFs to a level comparable to wild-type cells (Fig. 8F).

We also examined whether the FGF and WNT9B proteins have any effect on mesenchymal cell migration. The migratory behavior of mesenchymal cells in wound-healing and Transwell cell migration assays were unaffected by FGF or WNT9B (supplementary material Fig. S6).

Taken together, we conclude that WNT9B positively regulates FGF gene expression in the ectoderm of the NP and MxP, and that WNT9B-induced ectodermal FGF signaling is required for the proliferation of mesenchymal cells within the NPs and MxP (Fig. 8G).

**DISCUSSION**

**Wnt9b controls outgrowth of facial processes through the canonical WNT/β-catenin pathway**

The primary embryonic defect of facial development in \( Wnt9b^{−/−} \) mutants is hypoplasia with reduced outgrowth of the NPs and MxP (Fig. 2) as a direct consequence of reduced proliferation (Fig. 3). A subsequent failure of physical contact between the LNP and MNP at ~E10-11.5 prevents fusion between the facial processes (Fig. 2) and eventually results in cleft lip with cleft palate at later stages in \( Wnt9b^{−/−} \) mice (Fig. 1). Several lines of evidence confirm that these cellular defects result from compromised WNT/β-catenin signaling. A significant reduction in active β-catenin protein accumulation, in phosphorylation of the LRP6 receptor and in expression of WNT/β-catenin signaling reporter and downstream target genes in the NP and MxP were observed in \( Wnt9b^{−/−} \) embryos (Figs 4, 5). The recombinant WNT9B protein effectively increased WNT/β-catenin signaling in facial process explant cultures in vitro (Fig. 5). Furthermore, in utero LiCl treatment partially restored β-catenin activation in \( Wnt9b \) null embryos as assessed by target gene expression at E10.5-11 (Fig. 5G-K; supplementary material Fig. S4B). However, morphological defects, when observed in E13.5 embryos, were not rescued by in utero LiCl administration (data not shown), suggesting that the LiCl administration scheme (timing, dosage and frequency) might not be optimal for phenotypic rescue. Additionally, because GSK3β also plays a key role in the negative regulation of SHH signaling through the phosphorylation of the GLI2/3 transcription factors (Lum and Beachy, 2004), in utero LiCl treatment can activate SHH signaling simultaneously. A genetic approach to WNT signaling activation or the use of a more specific WNT signaling activator is warranted to determine whether the defects in \( Wnt9b^{−/−} \) embryos can be rescued by activation of β-catenin signaling.

Consistent with the phenotypes of \( Wnt9b \) mutants, \( Lrp6 \) mutant mice show a full penetrance of CL/P with retarded outgrowth of the NP and MxP (Song et al., 2009). In these mutant mice, severely reduced proliferation without apparent apoptosis is evident in mesenchymal cells of the NP and MxP (Song et al., 2009). Moreover, WNT9B protein has been shown to directly bind to the extracellular domain of the LRP6 receptor using an in vitro protein interaction assay (Bourhis et al., 2010; Gong et al., 2010), strongly suggesting that WNT9B transmits its signal through the LRP6 receptor in the facial processes.
Ectoderm-specific inactivation and activation of Ctnnb1 in the facial processes causes severe hypoplasia and hyperplasia of the facial processes, respectively (Reid et al., 2011; Wang et al., 2011). Mesenchyme-specific Ctnnb1 deletion in the facial processes also causes severe defects in facial development, with missing facial skeletal components accompanying significant hypoplasia in the frontofacial region and BA1 (Braullot et al., 2001). Interestingly, unlike Wnt9b and Lrp6 mutants, increased apoptosis without reduced proliferation was detected in both ectodermal and mesenchymal cells of the BA1 and NPs of Ctnnb1 deletion mutants (Braullot et al., 2001; Wang et al., 2011). Inactivation of Wnt9b or Lrp6 might only partially remove the activity of WNT/β-catenin signaling in the facial processes, as Lrp5 and other WNT genes can provide the remaining WNT signaling activity. Different cellular defects (proliferation versus apoptosis) observed in mice lacking Ctnnb1, Lrp6 or Wnt9b also strongly suggest that multiple cellular processes are regulated by WNT/β-catenin signaling within the facial processes.

**WNT9B cannot activate non-canonical WNT/PCP signaling during facial development**

A previous study demonstrated that Wnt9b also acts through the non-canonical WNT/PCP pathway, mainly the RHOA-JNK signaling cascade, during kidney development (Kamer et al., 2009). In contrast to kidney development, we failed to detect any indication of reduced (or induced) WNT/PCP signaling in the facial processes of Wnt9b−/− embryos (Fig. 6). In general, there is scant WNT/PCP signaling activity within these processes in wild-type embryos.

Consistent with this notion, ectoderm- and mesenchyme-specific deletion of Rac1, Cdc42 or Rhoa in the facial processes does not result in any notable phenotypic defects in facial structures until E10.5 (Chen et al., 2006; Fuchs et al., 2009; Thomas et al., 2010; Katayama et al., 2011). No morphological hypoplasia was found in the NP and MxP of mesenchyme-specific Rac1 and Cdc42 mutant mice at E11 (Fuchs et al., 2009; Thomas et al., 2010). Severe malformations of neural crest-derived structures and mid-facial cleft appeared in these mutants at ~E11.5.

Mice lacking both the Fzd1 and Fzd2 receptor genes exhibit signatures of defective WNT/PCP signaling, including a failure of closure in the palate, ventricular septum and neural tube, and misorientation of inner ear sensory hair cells (Yu et al., 2010). However, these mice still display normal development of the NP and MxP and lip fusion. Taken together, our results and previously published reports suggest that non-canonical WNT/PCP signaling plays insignificant or minimal roles within the NPs and MxP during the stage when the defects associated with Wnt9b null mutation are apparent.

**WNT/β-catenin signaling is required for FGF gene expression in facial process ectoderm to induce mesenchyme cell proliferation**

Reduced cell proliferation in mesenchymal cells of the facial processes in Wnt9b−/− embryos raises the question of whether ectoderm-derived WNT9B ligand can act as a mitogen for mesenchymal cells. The recombinant WNT9B protein failed to induce proliferation of primary facial mesenchyme cells in culture (Fig. 8), arguing that WNT9B might not be a mitogen that induces mesenchyme cell proliferation. Given the evident reduction of WNT/β-catenin signaling activity within the ectodermal layer of the NP and MxP in Wnt9b mutants, it is plausible that WNT9B might induce ectoderm-derived mitogens.

It is known that FGF signaling plays crucial roles in facial development. Among 22 FGF genes, at least seven (Fgf3, Fgf8, Fgf9, Fgf10, Fgf13, Fgf15 and Fgf18) are expressed with a regional specificity within the ectoderm of the facial processes in mice between E9.5 and E10.5 (Bachler and Neubuser, 2001). We found that Fgf8, Fgf10 and Fgf17 RNA expression and FGF-induced phosphorylation of ERK1/2 were significantly reduced in the NP and MxP of Wnt9b−/− embryos (Figs 7, 8). Ectoderm-specific activation of β-catenin in the facial processes resulted in increased expression of these FGF genes (Fig. 7M), strongly suggesting that they are targets for WNT/β-catenin signaling. Indeed, Fgf8 and Fgf10 were previously identified as direct WNT/β-catenin target genes in facial and cardiac tissues, respectively (Cohen et al., 2007; Wang et al., 2011).
cell apoptosis were observed (Reid et al., 2011; Wang et al., 2011). By contrast, because loss of Wnt9b or Lrp6 partially reduces FGF gene expression, the residual FGFs might protect cells from death but not support efficient cell proliferation.

Another possibility is a differential tissue response to FGFs. FGF signaling primarily controls cell survival in the MdP and telencephalon (Trumpp et al., 1999; Paek et al., 2009; Paek et al., 2011). Ablation of Ctnnb1 in the facial ectoderm induces more significant cell death in BA1 than in the NPs (Reid et al., 2011), suggesting that there might be a differential response to FGF signaling in these cells. These observations, including our present findings, suggest the interesting possibility that fine-tuned FGF signaling activity differentially regulates two distinct cellular behaviors, i.e. proliferation and survival, within the facial processes.

Acknowledgements
We thank Drs Thomas Gridley, Jin-Seon Lee, Lucy Liaw and Doug Spicer for comments and suggestions; Norma Albrecht for proofreading the manuscript; and Drs Thomas Carroll and Terry Yamaguchi for providing mouse lines.

Funding
This research was supported by National Institutes of Health grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [5R01 AR055278 to J.K.Y.] and the National Institute of General Medical Sciences (NIGMS) [BP20 GM103465 to J.K.Y.] (Program Director D. Wojchowski). The core facilities that support this work were funded by NIGMS (Histopathology and Bioinformatics cores, BP20 GM103465 to D. Wojchowski; Mouse Transgenic, Histopathology and DNA Analysis cores, BP30 GM103392 to R. Friesel). Deposited in PMC for release after 12 months.

Competing interests statement
The authors declare no competing financial interests.

Supplementary material
Supplementary material available online at http://dev.biologists.orglookup/suppl;doi:10.1242.dev.075796/-DC1

References


